摘要
目的探讨艾滋病合并结核病（AIDS／TB）病人以及普通AIDS病人在高效抗逆转录病毒治疗（HAART）过程中毒副作用的发生情况。方法以106例AIDS／TB病人作为病例组，以134例单纯AIDS病人作为对照组，观察和比较其实施HAART后1年内毒副作用的发生情况及CD4^＋T细胞计数上升水平。结果HAART1年后，病例组中出现毒副作用的有39例，占36．8％，对照组中出现毒副作用的有36例，占26．9％，两组比较差异无统计学意义（x^2=2．715，P=0．099）。绝大部分病例在接受HAART后CD4^＋T细胞显著上升（P〈0．01），且HAART后6个月对照组中CD4^＋T细胞上升幅度[（147．2±137．6）个／μl]高于病例组[（142．1±127．0）个／μl]，而HAART后9个月对照组中CD4^＋T细胞上升幅度[（166．5±133．1）个／μl]却低于病例组[（172．7±107．5）个／μl]，但差异均无统计学意义（P〉0．05）。结论HAART可使AIDS病人的免疫重建，HAART后AIDS／TB病人与普通AIDS病人的CD4^＋T细胞上升幅度无差异。另外，AIDS／TB病人HAART后其毒副作用的发生率并未明显增高。
Objective To investigate the problem of adverse effects in common AIDS patients and AIDS patients with tuberculosis after highly active antiretroviral therapy （HAART）. Methods The case group was composed of 106 patients with both AIDS and tuberculosis. The control group was composed of 134 common AIDS patients. The rates of adverse effects and the increase of CD4 ^＋ T cell count in those groups after first year HAART were observed and compared. Results The rates of adverse effects in the case group was 36. 8% ,which was more than that in the control group （26. 9% ）, but the difference was not significantly different（x^5 = 2. 715, P = 0. 099）. The count of CD4 ^＋ T cell in most of the patients was in- creased after HAART （ P 〈 0. 01 ）. The increase of CD4 ^＋ T cell count in the case group [ （ 147.2 ± 137.6）/μl] was higher that in the control group[ （ 142. 1 ± 127.0）/μl] after six months HAART vs. （ 166. 5 ± 133. 1）/μl in case group], and it was lower than that in control group after nine months HAART [ （ 172. 7± 107.5）/μl], however the difference was not significant （ P 〉 0.05 ）. Conclusions HAART could reconstruct the immunition of AIDS patients. The increase of CD4 ^＋ T cell count did not show significant difference between common AIDS patients and AIDS patients with tuberculosis after I4AART. AIDS patients with tuberculosis might not increase the risk of development of adverse effects during HAART.
出处
《中国医师杂志》
CAS
2011年第7期880-882,886,共4页
Journal of Chinese Physician
